Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
M&A Deal

TCGX Acquisition Corp. to Merge with TriGemX Bio in $361 Million Business Combination

TCGX Acquisition Corp. has signed a definitive agreement to merge with TriGemX Bio, valuing the biotech firm at a pre-money equity valuation of $361 million. The transaction, supported by a significant private investment, aims to accelerate the clinical development of a potential first-in-class migraine treatment.

Lab, research, laboratory, chemistry. Stock photo illustrating TCGX Acquisition's M&A deal story.
TCGX Acquisition Corp. · Financial Services · Photo: satheeshsankaran / Pixabay
Key numbers
Deal value$361M
Share of market cap259.6%

Key highlights

  • Pre-money equity valuation for TriGemX Bio established at $361 million
  • Secured $160 million in PIPE financing from top-tier healthcare investors
  • Combined company expected to receive approximately $246 million in gross proceeds
  • Post-transaction equity value projected to reach approximately $600 million
  • Targeting completion of Phase 3 clinical trials and New Drug Application submission

What Is the Deal?

TCGX Acquisition Corp. (NASDAQ: TCGX), a special purpose acquisition company, has entered into a definitive business combination agreement with TriGemX Bio, Inc., a biotechnology firm formerly known as Kallyope. The merger values TriGemX at a pre-money equity valuation of $361 million. Upon the anticipated closing in the first quarter of 2027, the combined entity will operate under the name TriGemX Bio, Inc. and is expected to list on the Nasdaq Stock Market under the new ticker symbol TGEM. The deal represents a significant pivot for the SPAC as it targets the high-growth pharmaceutical sector to address neurological diseases.

Deal Structure & Terms

  • Transaction includes a $160 million PIPE financing of common stock priced at $10.00 per share
  • TriGemX shareholders will receive no cash proceeds and roll 100% of their equity into the new company
  • Gross proceeds include approximately $86 million currently held in the TCGX trust account
  • TCGX will domesticate from the Cayman Islands to Delaware prior to the closing of the merger
  • Closing is subject to approval by shareholders of both companies and customary regulatory conditions
TCGX Acquisition Corp. share price · last month
Line chart of TCGX Acquisition Corp.'s share price over the last month, from $10.02 on 19 Oct → $10.00 on 16 Nov; our story on 19 Oct at $12.30.

Down 18.7% since our story on 19 Oct: $12.30 when we broke it → $10.00 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$10.02
20 Oct$10.01
21 Oct$10.00
22 Oct$10.03
23 Oct$10.10
26 Oct$10.14
27 Oct$10.10
28 Oct$10.09
29 Oct$10.06
30 Oct$10.04
2 Nov$10.03
3 Nov$10.03
4 Nov$10.04
5 Nov$10.03
6 Nov$10.04
9 Nov$10.05
10 Nov$10.04
11 Nov$10.04
12 Nov$10.03
13 Nov$10.01
16 Nov$10.00

Strategic Rationale

“With the anticipated proceeds from this transaction, TriGemX will be positioned to fully fund the Phase 3 development of elismetrep and undertake key commercial readiness activities as we prepare for a potential U.S. launch.”

Jeff Goater, CEO, TriGemX Bio

Business Overview

TriGemX Bio is dedicated to the development of elismetrep, a potential first-in-class acute treatment for migraine. This condition remains one of the world's most prevalent neurological diseases, and a substantial portion of the patient population fails to find adequate relief from current standard-of-care therapies. The company intends to use the merger proceeds to finalize ongoing Phase 3 clinical trials and prepare a New Drug Application for the U.S. Food and Drug Administration. Beyond acute treatment, the company is developing a distinct formulation of elismetrep for migraine prevention to broaden its footprint in the neurology market.

Financial Context

  • Combined company projected to have a post-transaction equity value of approximately $600 million
  • PIPE financing participants include Viking Global Investors, ADAR1 Capital Management, and BVF Partners
  • Current TCGX shares trade at $12.30, compared to the $10.00 per share entry point for PIPE investors
  • Proceeds will support commercial infrastructure and readiness activities ahead of a potential U.S. product launch

Management commentary

“This is an important day and financing for TriGemX. With the anticipated proceeds from this transaction, TriGemX will be positioned to fully fund the Phase 3 development of elismetrep and undertake key commercial readiness activities as we prepare for a potential U.S. launch.”

Jeff Goater, CEO of TriGemX Bio

“We are thrilled to partner with the team at TriGemX. We established TCGX, motivated by the opportunity to support high-potential life sciences companies developing groundbreaking therapies, and TriGemX exemplifies that vision.”

Chen Yu, CEO of TCGX Acquisition Corp.
TCGX Acquisition Corp. · financial snapshot
Share price$12.30
Market cap$139M
1-month price change-11.19%
SectorFinancial ServicesShell Companies

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by TCGX Acquisition Corp. announcing a definitive business combination agreement with TriGemX Bio, Inc.

Read the filing ↗

Track TCGX Acquisition Corp. live

Get the next TCGX Acquisition Corp. SEC filing seconds after it lands.

More in M&A & Deals

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.